Dawnrays Pharmaceutical Holdings Ltd. (HK:2348) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dawnrays Pharmaceutical Holdings Ltd. announced the appointment of Ms. Yu Liwei as the new CEO, effective from 13 September 2024. Ms. Yu, with a background in Biological Pharmaceutics and a history of managerial roles within the company, steps into the leadership position with a two-year contract. Her compensation includes an annual salary of HKD2,400,000 plus potential discretionary bonuses based on the company’s performance.
For further insights into HK:2348 stock, check out TipRanks’ Stock Analysis page.